← FDA DRUG APPROVALS

FDA ANDA · ANDA209201

AZITHROMYCIN

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA209201
TYPE
ANDA
ORIGINAL APPROVAL
2018-10-09
LATEST ACTION
2022-01-12
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

AZITHROMYCINPrescription
AZITHROMYCIN EQ 200MG BASE/5ML · FOR SUSPENSION · ORAL
AZITHROMYCINPrescription
AZITHROMYCIN EQ 100MG BASE/5ML · FOR SUSPENSION · ORAL

Approval history

2022-01-12Labeling · Supplement 4 · standardAP
2020-10-18Labeling · Supplement 3 · standardAP
2020-01-23Labeling · Supplement 2 · standardAP
2018-10-09UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →